6 unknown, 4 completed, 2 terminated, 2 withdrawn. 15 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Unknown 6, Completed 4, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 7 | Completed 2, Unknown 2, Withdrawn 2, Terminated 1 |
Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine PHH-1V81, Comirnaty Omicron XBB1.5 - SARS-CoV2 Infection | Phase 2 / Phase 3 | Completed | Hipra Scientific, S.L.U | 913 | 2023-11-15 | 2026-03-12 |
| PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway Nirmatrelvir/ritonavir, Placebo - Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection | Phase 3 | Active not recruiting | Haukeland University Hospital | 2000 | 2023-05-12 | 2025-11-21 |
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| SARS-CoV-2 and Acetylsalicylic Acid (SARA) Low-dose acetylsalicylic acid, Placebo - SARS-CoV2 Infection, Covid19 | Phase 3 | Completed | Barcelona Institute for Global Health | 38 | 2022-09-14 | 2024-08-15 |
| Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea Combination regimen: Fluoxetine, Prednisolone, Ivermectin, Combination regimen: Albendazole, Vitamin C - SARS-CoV2 Infection, COVID-19 | Phase 2 / Phase 3 | Withdrawn | Oriol Mitja | 2022-05-01 | 2023-03-09 | |
| PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 Galactomannan, PLACEBO - COVID-19, COVID-19 Pandemic | Phase 3 | Unknown | Bioxytran Inc. | 408 | 2022-04-01 | 2022-03-09 |
| Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above SARS-CoV-2 Vaccine, Inactivated (Vero Cell) - SARS-CoV2 Infection | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 880 | 2021-12-16 | 2022-02-16 |
| Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines GX-19N, Placebo - SARS-CoV2 Infection | Phase 2 / Phase 3 | Withdrawn | Genexine, Inc. | 2021-10-01 | 2022-04-12 | |
| A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients Recombinant cytokine gene derived protein injection - SARS-CoV2 Infection | Phase 3 | Unknown | Beijing 302 Hospital | 300 | 2021-08-31 | 2021-08-24 |
| Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT Atorvastatin 40 Mg Oral Tablet, Placebo - Covid19, SARS-CoV2 Infection | Phase 3 | Unknown | Mansoura University | 220 | 2021-08-14 | 2021-10-25 |
| Outpatient Treatment With Anti-Coronavirus Immunoglobulin Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo - COVID, SARS-CoV2 Infection | Phase 3 | Terminated | University of Minnesota | 741 | 2021-08-06 | 2026-08-13 |
| Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients Exosome-MSC Intravenous injection, Placebo Intravenous Injection, COVID-19 Standard Treatment - SARS-CoV2 Infection | Phase 2 / Phase 3 | Unknown | Dermama Bioteknologi Laboratorium | 60 | 2021-07-01 | 2022-02-18 |
| COVAXIN in a Pediatric Cohort COVAXIN - SARS-CoV2 Infection | Phase 2 / Phase 3 | Completed | Bharat Biotech International Limited | 525 | 2021-05-26 | 2022-08-18 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine SARS-CoV-2 vaccine (inactivated), Placebo - SARS-CoV2 Infection | Phase 3 | Completed | PT Bio Farma | 1620 | 2020-08-10 | 2022-01-13 |
COVID-19 (15) · Cytokine Release Syndrome (2) · Coronavirus Infections (1) · Infections (1)
Coronaviridae Infections (15) · Lung Diseases (15) · Nidovirales Infections (15) · Pneumonia (15) · Pneumonia, Viral (15) · RNA Virus Infections (15) · Respiratory Tract Diseases (15) · Respiratory Tract Infections (15) · Virus Diseases (15) · Coronavirus Infections (14) · Infections (14) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Shock (2)
COVID-19 Vaccines (2) · Tablets (2) · Acetaminophen (1) · Ascorbic Acid (1) · Aspirin (1) · Atorvastatin (1) · BBV152 COVID-19 vaccine (1) · Fluoxetine (1) · GX-19N vaccine (1) · HIV hyperimmune globulin (1) · Ivermectin (1) · Prednisolone (1) · Sodium Chloride (1) · Telmisartan (1) · fostamatinib (1)
ANRS, Emerging Infectious Diseases (1) · Barcelona Institute for Global Health (1) · Beijing 302 Hospital (1) · Bharat Biotech International Limited (1) · Bioxytran Inc. (1) · Chinese Academy of Medical Sciences (1) · Dermama Bioteknologi Laboratorium (1) · Genexine, Inc. (1) · Haukeland University Hospital (1) · Hipra Scientific, S.L.U (1) · Mansoura University (1) · NEAT ID Foundation (1) · Oriol Mitja (1) · PT Bio Farma (1) · University of Minnesota (1)
Spain (4) · Indonesia (2) · Argentina (1) · Australia (1) · Brazil (1) · Burkina Faso (1) · China (1) · Denmark (1) · Egypt (1) · Germany (1) · Greece (1) · Guinea (1) · India (1) · Italy (1) · Malaysia (1)
Anton Pozniak, Prof (1) · Bambang Darwono, Dr.Sp.OT (1) · Cavan Reilly, PhD (1) · Dr Mirza Nizam Baig, MBBS,MD (1) · Dr Padmavathi I V, MBBS,MD (1) · Dr Prashanth Siddiah, MBBS,MD (1) · Dr.Jai Prakash Narayan, MBBS,MD (1) · Dr.Lokesh Kumar Tiwari, MBBS,DNB (1) · Dr.V.N Tripathi, MBBS,MD (1) · Dr.Vasant Khalatkar, MBBS,MD (1) · Indah H Kampono, Dr. Sp.DV (1) · JungWon Woo, Ph.D. (1) · Moataz M Emara, MD, EDAIC (1) · Nina Langeland, MD, PhD (1)
PMID 35717995, PMID 35941669, PMID 36216961, PMID 36574985, PMID 37489818, PMID 38389078, PMID 41199272, PMID 42462744